1. +
Acetadote package insert. Nashville, TN: Cumberland Pharmaceuticals, Inc., December2008.
2. +
ACT investigators.
Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography. Main results from the randomized
acetylcysteine for contrast-induced nephropathy trial (ACT).
Circulation. 2011;124:1250–1259.
3. +
Agarwal
A, Munoz-Najar
U, Klueh
U
et al.: N-acetyl-cysteine promotes angiostatin production and vascular collapse in an orthotopic model of breast cancer. Am J Pathol. 2004;164:1683–1696.
4. +
Aloha
T, Fellman
V, Laaksonen
R
et al.: Pharmacokinetics of intravenous N-acetylcysteine in pre-term new-born infants. Eur J Clin Pharmacol. 1999;55:645–650.
5. +
Allaqaband
S, Tumuluri
R, Malik
AM
et al.: Prospective randomized study of N-acetylcysteine,
fenoldopam, and saline for prevention of radiocontrast-induced nephropathy.
Cathet Cardiovasc Intervent. 2002;57:279–283.
6. +
Anonymous. Death after N-acetylcysteine. Lancet. 1984;1:1421.
7. +
Appelboam
AV, Dargan
PI, Knighton
J: Fatal anaphylactoid reaction to N-acetylcysteine: caution in patients with asthma. Emerg Med J. 2002;19:594–595.
8. +
Appenroth
D, Winnefeld
K, Heinz
S
et al.: Beneficial effect of
acetylcysteine on
cisplatin nephrotoxicity in rats.
J Appl Toxicol. 1993;13:189–198.
9. +
Aw
MM, Dhawan
A, Baker
AJ, Mieli-Vergani
G: Neonatal paracetamol poisoning. Arch Dis Child Fetal Neonatal Ed. 1999;81:F78.
10. +
Bailey
B, Blais
R, Letarte
A: Status epilepticus after a massive intravenous N-acetylcysteine overdose leading to intracranial hypertension and death. Ann Emerg Med. 2004;44:401–406.
11. +
Bailey
B, McGuigan
M: Management of anaphylactoid reactions to intravenous N-acetylcysteine. Ann Emerg Med. 1998;31:710–715.
12. +
Baker
CSR, Wragg
A, Kumar
S
et al.: A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol. 2003;41:2114–2118.
13. +
Ballatori
N, Lieberman
MW, Wang
W: N-acetylcysteine as an antidote in methylmercury poisoning. Environ Health Perspect. 1998;106:267–271.
14. +
Baltzer
WI, McMichael
MA, Hosgood
GL
et al.: Randomized, blinded, placebo-controlled clinical trials of N-acetylcysteine in dogs with spinal cord trauma from acute intervertebral disc disease. Spine. 2008;33:1397–1402.
15. +
Banner
W
Jr, Koch
M, Capin
DM
et al.: Experimental chelation therapy in chromium, lead, and boron intoxication with N-acetylcysteine and other compounds. Toxicol ApplPharmacol. 1986;83:142–147.
16. +
Barrett
KE, Minor
JR, Metcalfe
DD: Histamine secretion induced by N-acetyl
cysteine.
Agents Actions. 1985;16:144–146.
17. +
Bateman
DN, Woodhouse
KW, Rawlins
MD: Adverse reactions to N-acetylcysteine. Hum Toxicol. 1984;3:393–398.
18. +
Berk
M, Malhi
GS, Gray
LJ
et al.: The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol Sci. 2013;34:167–177.
19. +
Betten
DP, Cantrell
FL, Thomas
SC
et al.: A prospective evaluation of shortened course oral N-acetylcysteine for the treatment of acute
acetaminophen poisoning.
Ann Emerg Med. 2007;50:272–279.
20. +
Ben-Ari
Z, Vaknin
H, Tur-Kaspa
R: N-acetylcysteine in acute hepatic failure (non-paracetamol-induced). Hepatogastroenterology. 2000;47:786–789.
21. +
Boccalandro
F, Amhad
M, Smalling
RW, Sdringola
S: Oral
acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast.
Cathet Cardiovasc Intervent. 2003;58:336–341.
22. +
Bond
GR: Is the oral
acetylcysteine protocol the best treatment for late-presenting
acetaminophen poisoning?
Clin Toxicol. 2009;54:615–616.
23. +
Bonfiglio
M, Traeger
S, Hulisz
D
et al.: Anaphylactoid reaction to IV
acetylcysteine associated with electrocardiographic abnormalities.
Pharmacotherapy. 1992;26:22–25.
24. +
Borgstrom
L, Kagedal
B, Paulsen
O: Pharmacokinetics of N-acetylcysteine in man. Eur J Clin Pharmacol. 1986;31:217–222.
25. +
Briguori
C, Manganelli
F, Scarpato
P
et al.:
Acetylcysteine and contrast agent-associated nephrotoxicity.
J Am Coll Cardiol. 2002;40:298–303.
26. +
Bromley
PN, Cottam
SJ, Hilmi
I
et al.: Effects of intraoperative N-acetylcysteine in orthotopic liver transplantation. Br J Anaesth. 1995;75:352–354.
27. +
Brush
DE, Boyer
EW: Intravenous N-acetylcysteine for children. Pediatr Emerg Care. 2004;20:649–650.
28. +
Buckley
N, Whyte
I, O’Connell
DL, Dawson
A: Activated charcoal reduces the need for N-acetylcysteine treatment after
acetaminophen (paracetamol) overdose.
J Toxicol Clin Toxicol. 1999;37:753–757.
29. +
Buckpitt
AR, Rollins
DE, Mitchell
JR: Varying effects of sulfhydryl nucleophiles on
acetaminophen oxidation and sulfhydryl adduct formation.
Biochem Pharmacol. 1979;28:2841–2946.
30. +
Chinough
R, Czajka
P: N-Acetylcysteine adsorption by activated charcoal. Vet Hum Toxicol. 1980;22:392–394.
31. +
Chyka
P, Butler
A, Holliman
B, Herman
M: Utility of
acetylcysteine in treatment poisonings and adverse drug reactions.
Drug Saf. 2000;2:123–148.
32. +
Coulson
J, Thompson
JP: Paracetamol (
acetaminophen) attenuates in vitro mast cell and peripheral blood mononucleocyte cell histamine release induced by N-acetylcysteine.
Clin Toxicol. 2010;48:111–114.
33. +
Crowell
C, Lyew
RV, Givens
M
et al.: Caring for the mother, concentrating on the fetus: intravenous N-acetylcysteine in pregnancy. Am J Emerg Med. 2008;6:735–738.
34. +
Dart
R, Rumack
B: Patient tailored
acetylcysteine administration.
Ann Emerg Med. 2007;50:280–281.
35. +
Dawson
A, Henry
D, McEwen
J: Adverse reactions to N-acetylcysteine during treatment for paracetamol poisoning. Med J Aust. 1989;150:329–331.
36. +
De Backer
WA, Amsel
B, Jorens
PG
et al.: N-Acetylcysteine pretreatment of cardiac surgery patients influences plasma neutrophil elastase and neutrophil influx in bronchoalveolar lavage fluid. Intensive Care Med. 1996;22:900–908.
37. +
De Flora
S, Cesarone
CE, Balansky
RM
et al.: Chemopreventive properties and mechanisms of N-acetylcysteine. The experimental background. J Cell Biochem. 1995;22(suppl):33–41.
38. +
Devlin
J, Ellis
AE, McPeake
J
et al.: N-acetylcysteine improves indocyanine green extraction and
oxygen transport during hepatic dysfunction.
Crit Care Med. 1997;25:236–242.
39. +
Diaz-Sandoval
LJ, Kosowsky
BD, Losordo
DW:
Acetylcysteine to prevent angiography-related renal tissue injury (The APART Trial).
Am J Cardiol. 2002;89:356–358.
40. +
Doyon
S, Klein-Schwartz
W: Hepatotoxicity despite early administration of intravenous N-acetylcysteine for acute
acetaminophen overdose.
Acad Emerg Med. 2009;16:34–39.
41. +
Dribben
WH, Porto
SM, Jeffords
BK: Stability and microbiology of inhalant N-acetylcysteine used as an intravenous solution for the treatment of
acetaminophen poisoning.
Ann Emerg Med. 2003;42:9–13.
42. +
Duncan
R, Cantlay
G, Paterson
B: New recommendation for N-acetylcysteine dosing may reduce incidence of adverse effects. Emerg Med J. 2006;23:584–585.
43. +
Durham
JD, Caputo
C, Dokko
J
et al.: A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int. 2002;62:2202–2207.
44. +
Eisen
JS, Koren
G, Juurlink
DN
et al.: N-acetylcysteine for the treatment of clove oil-induced fulminant hepatic failure. Clin Toxicol. 2004;42:89–92.
45. +
Ekins
B, Ford
D, Thompson
M
et al.: The effect of activated charcoal on N-acetylcysteine absorption in normal subjects. Am J Emerg Med. 1987;5:483–487.
46. +
Enjalbert
F, Rapior
S, Nouguier-Soule
J
et al.: Treatment of amatoxin poisoning: 20-year retrospective analysis. Clin Toxicol. 2002;40:715–757.
47. +
Flanagan
R, Meredith
TJ: Use of N-acetylcysteine in clinical toxicology. Am J Med. 1991;91:131S–139S.
48. +
Gawarammana
IB, Greene
SL, Dargan
PI, Jones
AL: Australian Clinical Toxicology Investigators Collaboration randomized trial of different loading infusion rates of N-acetylcysteine. Ann Emerg Med. 2006;47:124.
49. +
Gervais
S, Lussier-Labelle
F, Beaudet
G: Anaphylactoid reaction to
acetylcysteine.
Clin Pharm. 1984;3:586–587.
50. +
Goldenberg
I, Shechter
M, Matetzky
S
et al.: Oral
acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography.
Eur Heart J. 2004;25:212–218.
51. +
Gonzales
DA, Norsworthy
KJ, Kern
SJ
et al.: A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity. BMC Med. 2007;5:32.
52. +
Gundersen
Y, Vaagenes
P, Thrane
I
et al.: N-acetylcysteine administered as part of the immediate post-traumatic resuscitation regimen does not significantly influence initiation of inflammatory responses or subsequent endotoxin hyporesponsiveness. Resuscitation. 2005;64:377–382.
53. +
Hanly
LN, Chen
N, Aleksa
K
et al.: N-acetylcysteine as a novel prophylactic treatment for ifosfamide-induced nephrotoxicity in children: translational pharmacokinetics. J Clin Pharmacol. 2012;52:55–64.
54. +
Harrison
P, Keays
R, Bray
G
et al.: Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of
acetylcysteine.
Lancet. 1990;335:1572–1573.
55. +
Harrison
P, Wendon
J, Gimson
A
et al.: Improvement by
acetylcysteine of hemodynamics and
oxygen transport in fulminant hepatic failure.
N Engl J Med. 1991;324:1852–1857.
56. +
Hayes
B, Klein-Schwartz
W, Dyon
S: Frequency of medication errors with intravenous
acetylcysteine for
acetaminophen overdose.
Ann Pharmacotherapy. 2008;42:766–770.
57. +
Heard
K: A multicenter comparison of the safety of oral versus intravenous
acetylcysteine for treatment of
acetaminophen overdose.
Clin Toxicol. 2010;48:424–430.
58. +
Heard
K, Schaeffer
TH: Massive
acetylcysteine overdose associated with cerebral edema and seizures.
Clin Toxicol. 2011;49:423–425.
59. +
Henderson
P, Hale
TW, Shum
S: N-acetylcysteine therapy of acute heavy metal poisoning in mice. Vet Human Toxicol. 1985;27:522–525.
60. +
Ho
SW, Beilin
JJ: Asthma associated with N-acetylcysteine infusion and paracetamol poisoning: report of two cases. Br Med J. 1983;287:876–877.
61. +
Holdiness
MR: Clinical pharmacokinetics of N-acetylcysteine. Clin Pharm. 1991;20:123–134.
62. +
Holt
S, Goodier
D, Marley
R
et al.: Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet. 1999;353:294–295.
63. +
Horowitz
BZ, Hendrickson
RG, Pizarro-Osilla: Not so fast!Ann Emerg Med. 2006;47:122–123.
64. +
Horowitz
R, Dart
R, Jarvie
D
et al.: Placental transfer of N-acetylcysteine following human maternal
acetaminophen toxicity.
J Toxicol Clin Toxicol. 1997;35:447–451.
65. +
Jepsen
S, Hansen
AB: The influence of N-acetylcysteine on the measurement of prothrombin time and activated partial thromboplastin time in healthy subjects. Scand JClin Lab Invest. 1994;54:543–547.
66. +
Johnson
D, Simone
C, Koren
G: Transfer of N-acetylcysteine by the human placenta. Vet Hum Toxicol. 1993;35:365.
67. +
Jones
A, Jarvie
D, Simpson
D
et al.: Pharmacokinetics of N-acetylcysteine are altered in patients with chronic liver disease. Aliment Pharmacol Ther. 1997;11:787–791.
68. +
Kao
LW, Kirk
MA, Furbee
RB: What is the rate of adverse events after oral N-acetylcysteine administered by the intravenous route to patients with suspected
acetaminophen poisoning?
Ann Emerg Med. 2003;42:741–750.
69. +
Kawaji
A, Sone
T, Natsuki
R
et al.: In vitro toxicity test of poisonous mushroom extracts with isolated rat hepatocytes. J Toxicol Sci. 1990;15:145–156.
71. +
Keays
R, Harrison
P, Wendon
J
et al.: Intravenous
acetylcysteine in paracetamol-induced fulminant hepatic failure: a prospective controlled trial.
Br Med J. 1991;303:1026–1029.
72. +
Kerr
F, Dawson
A, Whyte
I
et al.: The Australasian clinical toxicology intervention collaboration randomized trial of different loading infusion rates of N-acetylcysteine. Ann Emerg Med. 2005;45:402–409.
73. +
Klein Schwartz
W, Oderda
G: Adsorption of oral antidotes for
acetaminophen poisoning (methionine and N-acetylcysteine) by activated charcoal.
Clin Toxicol. 1981;18:283–290.
74. +
Kobrinsky
NL, Hartfield
D, Horner
H
et al.: Treatment of advanced malignancies with high-dose
acetaminophen and N-acetylcysteine rescue.
Cancer Invest. 1996;14:202–210.
75. +
Kortsalioudaki
C, Taylor
R, Cheeseman
P
et al.: Safety and efficacy of N-acetylcysteine in children with non-acetaminophen-induced acute liver failure. Liver Transplant. 2008;14:25–30.
76. +
Kshirsagar
AV, Poole
C, Mottl
A
et al.: N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. J Am Soc Nephrol. 2004;15:761–769.
77. +
Lauterburg
BH, Corcoran
GB, Mitchell
JR: Mechanism of action of N-acetylcysteine in the protection against the hepatotoxicity of
acetaminophen in rats.
J Clin Invest. 1983;71:980–991.
78. +
Lauterburg
BH, Velez
M: Glutathione deficiency in alcoholics: risk factor for paracetamol hepatotoxicity. Gut. 1988;29:1153–1157.
79. +
Lavonas
EJ, Farhood
A, Hopper
RD
et al.: Intravenous administration of N-acetylcysteine: oral and parenteral formulations are both acceptable. Ann Emerg Med. 2005;45:223–224.
80. +
Lederman
S, Fysh
WJ, Tredger
M, Gamsu
HR: Neonatal paracetamol poisoning: treatment by exchange transfusion. Arch Dis Child. 1983;58:631–633.
81. +
Lee
WM, Hynan
LS, Rossaro
L
et al.: Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009;137:856–864.
82. +
Leonis
M, Balistreri
W: Is there a “NAC” to treating acute liver failure. Liver Transplant. 2008;14:7–8.
83. +
Linden
CH, Rumack
BH:
Acetaminophen overdose.
Emerg Med Clin North Am. 1984;2:103–119.
84. +
Lovat
R, Preiser
JC: Antioxidant therapy in intensive care. Curr Opin Crit Care. 2003;9:266–270.
85. +
Lucena
MI, Lopez-Torres
E, Verge
C: The administration of Nacetylcysteine causes a decrease in prothrombin time in patients with paracetamol overdose but without evidence of liver impairment. Eur J Gastroenterol Hepatol. 2005;17:59–63.
86. +
Lynch
RM, Robertson
R: Anaphylactoid reactions to intravenous Nacetylcysteine: a prospective case controlled study. Accid Emerg Nurs. 2004;12:10–15.
87. +
Mahmoud
KM, Ammar
AS: Effect of N-acetylcysteine on cardiac injury and oxidative stress after abdominal aortic aneurysm repair: a randomized controlled trial. Acta Anaesthiol Scand. 2011;55:1015–1021.
88. +
Makipour
K, Friedenberg
FK: The potential role of N-acetylcysteine for the treatment of Helicobacter pylori. J Clin Gastroenterol. 2011;45:841–843.
89. +
Manini
AF, Snider
C: Intravenous loading infusion rates of N-acetylcysteine. Ann Emerg Med. 2006;47:123.
90. +
Mant
TGK, Tompowski
JH, Volans
GN, Talbot
JC: Adverse reactions to
acetylcysteine and effects of overdose.
Br Med J. 1984;289:217–219.
91. +
Marenzi
G, Assanelli
E, Marana
I
et al.: N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med. 2006;354:2773–2882.
92. +
Marchetti
A, Rossiter
R: Managing acute
acetaminophen poisoning with oral versus intravenous N-acetylcysteine: a provider-perspective cost analysis. J Med Econ 2009;12:384–391.
93. +
Martello
JL, Pummer
TL, Krenzelok
EP: Cost minimization analysis comparing enteral N-acetylcysteine to intravenous
acetylcysteine in the management of acute
acetaminophen toxicity.
Clin Toxicol. 2010;48:79–83.
94. +
Merl
W, Koutsogiannis
Z, Kerr
D, Kelly
AM: How safe is intravenous N-acetylcysteine for the treatment of paracetamol poisoning. Hong Kong J Emerg Med. 2007;14:198–203.
95. +
Miller
MA, Navarro
M, Bird
SB, Donovan
JL: Antiemetic use in
acetaminophen poisoning: how does the route of N-acetylcysteine administration affect utilization?
J Med Toxicol. 2007;3:152–156.
96. +
Mitchell
JR, Thorgeirsson
SS, Potter
WZ
et al.: Acetaminophen-induced hepatic injury: protective role of glutathione in man and rationale for therapy. Clin Pharmacol Ther. 1974;16:676–684.
97. +
Mour
G, Feinfeld
DA, Caraccio
T, McGuigan
M: Acute renal dysfunction in
acetaminophen poisoning.
Renal Failure. 2005;27:381–383.
98. +
Mullins
ME, Vitkovitsky
IV: Hemolysis and hemolytic uremic syndrome following five-fold N-acetylcysteine overdose. Clin Toxicol. 2011;49:755–759.
99. +
Mullins
ME, Schmidt
RU
Jr, Jang
TB: What is the rate of adverse events with intravenous versus oral N-acetylcysteine in pediatric patients?Ann Emerg Med. 2004;44:547–548.
100. +
Nolan
TD, Ouseph
R, Himmelfarb
J
et al.: Multiple-dose pharmacokinetics and pharmacodynamics of N-acetylcysteine in patients with end-stage renal disease. Clin J Am Soc Nephrol. 2010;5:1588–1594.
101. +
North
D, Peterson
RG, Krenzelok
E: Effect of activated charcoal administration on
acetylcysteine serum levels in humans.
Am J Hosp Pharm. 1981;38:1022–1024.
102. +
Nur
E, Brandjes
DP, Teerlink
T
et al.: N-acetyulcysteine reduces oxidative stress in sickle cell patients. Ann Hematol. 2012;91:1097–1105.
103. +
Ozcan
EE, Guneri
S, Akdeniz
B
et al.: Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial. Am Heart J. 2007;154:539–544.
104. +
Peake
J, Suzuki
K: Neutrophil activation, antioxidant supplements and exercise-induced oxidative stress. Exerc Immunol Rev. 2004;10:129–141.
105. +
Pendyala
L, Creaven
PJ: Pharmacokinetic and pharmacodynamic studies of N-acetylcysteine, a potential chemopreventive agent during a phase 1 trial. Cancer Epidemiol Biomarkers Prev. 1995;4:245–251.
106. +
Piperno
E, Berssenbruegge
DA: Reversal of experimental paracetamol toxicosis with N-acetylcysteine. Lancet. 1976;2:738–739.
107. +
Pizon
AF, Jang
DH, Wang
HE: The in vitro effect of N-acetylcysteine on prothrombin time in plasma samples from healthy subjects.
Acad Emerg Med. 2011;18;351–354.
CrossRef
[PubMed: 21496136]
108. +
Pizon
AF, LoVecchio
F: Adverse reaction from use of intravenous N-acetylcysteine. J Emerg Med. 2006;31:434–435.
109. +
Porta
R, Sanchez
L, Nicolas
M
et al.: Lack of toxicity after paracetamol overdose in a extremely preterm neonate. Eur J Clin Pharmacol. 2012;68:901–902.
110. +
Prescott
LF, Sutherland
GR, Park
J
et al.:
Cysteamine, methionine, and
penicillamine in the treatment of paracetamol poisoning.
Lancet. 1976;2:109–113.
111. +
Prescott
LF, Donovan
JW, Jarvie
DR
et al.: The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol over-dosage. Eur J ClinPharmacol. 1989;37:501–506.
112. +
Prescott
LF, Illingworth
RN, Critchley
JAJH
et al.: Intravenous N-acetylcysteine: the treatment of choice for paracetamol poisoning. Br Med J. 1979;2:1097–1100.
113. +
Prescott
LF, Newton
RW, Swainson
CP
et al.: Successful treatment of severe paracetamol overdosage with
cysteamine.
Lancet. 1974;1:588–592.
114. +
Prescott
L: Oral or intravenous N-acetylcysteine for
acetaminophen poisoning?
Ann Emerg Med. 2005;45:409–413.
115. +
Rank
N, Michel
C, Haertel
C
et al.: N-acetylcysteine increases liver blood flow and improves liver function in septic shock patients: results of a prospective, randomized, double-blind study. Crit Care Med. 2000;28:3799–3807.
116. +
Reliene
R, Fischer
E, Schiestl
R: The effect of N-acetylcysteine
cysteine on oxidative DNA damage and the frequency of DNA deletions in atm-deficient mice.
Cancer Res. 2004;64:5148–5153.
117. +
Renzi
F, Donovan
J, Morgan
L
et al.: Concomitant use of activated charcoal and N-acetylcysteine. Ann Emerg Med. 1985;14:568–572.
118. +
Reynard
K, Riley
A, Walker
BE: Respiratory arrest after N-acetylcysteine for a paracetamol overdose. Lancet. 1992;340:675.
119. +
Riggs
BS, Bronstein
AC, Kulig
KW
et al.: Acute
acetaminophen overdose during pregnancy.
Obstet Gynecol. 1989;74:247–253.
120. +
Roberts
DW, Bucci
TJ, Benson
RW
et al.: Immunohistochemical localization and quantification of the 3 (cystein-5-yl)
acetaminophen protein adduct in
acetaminophen hepatotoxicity.
Am J Pathol. 1991;138:359–371.
121. +
Roberts
I, Robinson
M, Mughal
MZ
et al.: Paracetamol metabolites in the neonate following maternal overdose. Br J Clin Pharmacol. 1984;18:201–201.
122. +
Roller
A, Weller
M: Antioxidants specifically inhibit
cisplatin cytotoxicity of human malignant glioma cells.
Anticancer Res. 1998;18:4493–4498.
123. +
Ruffmann
R, Wendel
A: GSH rescue by N-acetylcysteine. Klin Wochenschr. 1991;69:857–862.
124. +
Rumack
BH, Bateman
DN:
Acetaminophen and
acetylcysteine dose and duration: past, present, and future.
Clin Toxicol. 2012;50:91–98.
125. +
Rumack
BH:
Acetaminophen toxicity: the first 35 years.
J Toxicol Clin Toxicol. 2002;40:3–20.
126. +
Rumack
BH, Peterson
RG:
Acetaminophen overdose: incidence, diagnosis and management in 416 patients.
Pediatrics. 1978;62(Suppl):898–903.
127. +
Rybolt
T, Burrell
D, Shults
J, Kelley
A: In vitro coadsorption of
acetaminophen and N-acetylcysteine onto activated carbon powder.
J Pharm Sci. 1986;75:904–905.
128. +
Safirstein
R, Andrade
L, Vieira
J:
Acetylcysteine and nephrotoxic effects of radiographic contrast agents—a new use for an old drug.
N Engl J Med. 2000;343:210–212.
129. +
Saito
C, Zwingmann
C, Jaeschke
H: Novel mechanisms of protection against
acetaminophen hepatotoxicity in mice by glutathione and N-acetylcysteine.
Hepatology. 2010;51:246–254.
130. +
Sandilands
EA, Bateman
DN: Adverse reactions associated with
acetylcysteine.
Clin Toxicol. 2009;47:81–88.
131. +
Schaller
G, Pleiner
J, Mittermayer
F
et al.: Effects of N-acetylcysteine against systemic and renal hemodynamic effects of endotoxin in healthy humans. Crit Care Med. 2007;35:1869–1875.
132. +
Schwartz
EA, Hayes
BD, Sarmiento
KF: Development of hepatic failure despite use of intravenous
acetylcysteine after a massive ingestion of
acetaminophen and
diphenhydramine.
Ann Emerg Med. 2009;54:421–423.
133. +
Selden
BS, Curry
SC, Clark
RF
et al.: Transplacental transport of N-acetylcysteine in an ovine model. Ann Intern Med. 1991;20:1069–1072.
134. +
Sharma
A, Howland
MA, Hoffman
RS
et al.: The dilemma of NAC therapy in a premature infant. J Toxicol Clin Toxicol. 2000;38:57.
135. +
Shayani-Jam
H, Nematollahi
D: Electrochemical evidences in oxidation of
acetaminophen in the presence of glutathione and N-acetylcysteine.
Chem Commun. 2010;46:409–411.
136. +
Shen
F, Coulter
CV, Isbister
GK, Duffull
SB: A dosing regimen for immediate N-acetylcysteine treatment for acute paracetamol overdose. Clin Toxicol. 2011;49:643–647.
137. +
Shriner
K, Goetz
M: Severe hepatotoxicity in a patient receiving both
acetaminophen and
zidovudine.
Am J Med. 1992;93:94–96.
138. +
Shyu
KG, Cheng
JJ, Kuan
P:
Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure.
J Am Coll Cardiol. 2002;40:1383–1388.
139. +
Slattery
JT, Wilson
JM, Kalhorn
TF, Nelson
SD: Dose-dependent pharmacokinetics of
acetaminophen: evidence of glutathione depletion in humans.
Clin Pharmacol Ther. 1987;41:413–418.
140. +
Smilkstein
MJ, Bronstein
AC, Linden
CH
et al.:
Acetaminophen overdose: a 48-hour intravenous N-acetylcysteine protocol.
Ann Emerg Med. 1991;20:1058–1063.
141. +
Smilkstein
MJ, Knapp
GL, Kulig
KW
et al.: Efficacy of oral N-acetylcysteine in the treatment of
acetaminophen overdose. Analysis of the national multicenter study (1976–1985).
N Engl J Med. 1988;319:1557–1562.
142. +
Smith
SW, Howland
MA, Hoffman
RS, Nelson
LS:
Acetaminophen overdose with altered
acetaminophen pharmacokinetics and hepatotoxicity associated with premature cessation of intravenous N-acetylcysteine therapy.
Ann Pharmacother. 2008;42:1333–1339.
143. +
Sochman
J: N-acetylcysteine in acute cardiology: 10 years later: what do we know and what would we like to know?J Am Coll Cardiol. 2002;39:1422–1428.
144. +
Sochman
J, Vrbska
J, Musilova
B
et al.: Infarct size limitation: acute N-acetylcysteine defense (ISLAND) trial. Start of the study. Int J Cardiol. 1995;49:181–182.
145. +
Spapen
HD, Diltoer
MW, Nguyen
DN
et al.: Effects of N-acetylcysteine on microalbuminuria and organ failure in acute severe sepsis: results of a pilot study. Chest. 2005;127:1413–1419.
146. +
Spies
CD, Reinhart
K, Witt
I
et al.: Influence of N-acetylcysteine on indirect indicators of tissue oxygenation in septic shock patients. Crit Care Med. 1994;22:1738–1746.
147. +
Squires
RH, Dhawan
A, Alonso
E
et al.: Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: a placebo controlled trial. Hepatology. 2013;57:1542–1549.
148. +
Stav
D, Raz
M: Effect of N-acetylcysteine on air trapping in COPD. A randomized placebo-controlled trial. Chest. 2009;136:381–386.
149. +
Stravitz
RT, Kramer
AH, Davern
T
et al.: Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group.Crit Care Med. 2007;35:2498–2508.
150. +
Sung
L, Simons
J, Dayneka
N: Dilution of intravenous N-acetylcysteine as a cause of hyponatremia. Pediatrics. 1997;100:389–391.
151. +
Tayman
C, Tonbul
A, Kosus
A
et al.: N-acetylcysteine may prevent severe intestinal damage in necrotizing enterocolitis.
J Ped Surg. 2012:47;540–550.
CrossRef152. +
Tepel
M, VanDer Giet
M, Schwarzfeld
C
et al.: Prevention of radiographic-contrast-agent-induced reductions in renal function by
acetylcysteine.
N Engl J Med. 2000;343:180–184.
153. +
Thomale
UW, Griebenow
M, Kroppenstedt
SN
et al.: The effect of N-acetylcysteine on posttraumatic changes after controlled cortical impact in rats. Intensive Care Med. 2006;32:149–155.
154. +
Thomassen
D, Knebel
N, Slattery
JT, McClanahan
RH, Nelson
SD: Reactive intermediates in the oxidation of menthofuran by cytochromes P-450. Chem Res Toxicol. 1992;5:123–130.
155. +
Thomassen
D, Slattery
JT, Nelson
SD: Menthofuran-dependent and independent aspects of pulegone hepatotoxicity: roles of glutathione. J Pharmacol Exp Ther. 1990;253:567–572.
156. +
Thompson
DC, Barhoumi
R, Burghardt
RC: Comparative toxicity of eugenol and its
quinine methide metabolite in cultured liver cells using kinetic fluorescence bioassays.
Toxicol Appl Pharmacol. 1998;149:55–63.
157. +
Thompson
DC, Constantin-Teodosiu
D, Egestad
B
et al.: Formation of glutathione conjugates during oxidation of eugenol by microsomal fractions of rat liver and lung. Biochem Pharmacol. 1990;39:1587–1595.
158. +
Tong
TC, Hernandez
M, Richardson
WH
3rd
et al.: Comparative treatment of alpha-amanitin poisoning with N-acetylcysteine, benzylpenicillin,
cimetidine, thioctic acid, and silybin in a murine model.
Ann Emerg Med. 2007;50:282–283.
159. +
Traub
SJ, Mitchell
AM, Jones
AE
et al.: N-acetylcysteine plus intravenous fluids versus intravenous fluids alone to prevent contrast-induced nephropathy in emergency computed tomography.
Ann Emerg Med. 2013;62:511–520.
CrossRef
[PubMed: 23769807]
161. +
Vale
JA, Wheeler
DC: Anaphylactoid reactions to N-acetylcysteine. Lancet. 1982;2:988.
162. +
Valles
EG, de Castro
CR, Castro
JA: N-acetyl
cysteine is an early but also a late preventive agent against carbon tetrachloride-induced liver necrosis.
Toxicol Lett. 1994;71:87–95.
163. +
Walsh
TS, Lee
A: N-Acetylcysteine administration in the critically ill. Intensive Care Med. 1999;25:432–434.
164. +
Walsh
TS, Hopton
P, Philips
BJ
et al.: The effect of N-acetylcysteine on
oxygen transport and uptake in patients with fulminant hepatic failure.
Hepatology. 1998;27:1332–1340.
165. +
Walton
NG, Mann
TN, Shaw
KM: Anaphylactoid reaction to N-acetylcysteine. Lancet. 1979;2:1298.
166. +
Waring
WS, Stephen
AF, Robinson
OD: Lower incidence of anaphylactoid reactions to N-acetylcysteine in patients with high
acetaminophen concentrations after overdose.
Clin Toxicol. (Phila). 2008;46:496–500.
167. +
Wasserman
GS, Garg
U: Intravenous administration of N-acetylcysteine: interference with coagulopathy testing. Ann Emerg Med. 2004;44:546–547.
168. +
Whyte
IM, Francis
B, Dawson
AH: Safety and efficacy of intravenous N-acetylcysteine for
acetaminophen overdose: analysis of the Hunter Area Toxicology Service (HATS) database.
Curr Med Res Opin. 2007;23:2359–2368.
169. +
Wolchok
JD, Williams
L, Pinto
JT
et al.: Phase I trial of high dose paracetamol and
carmustine in patients with metastatic melanoma.
Melanoma Res. 2003;13:189–196.
170. +
Woo
OF, Mueller
PD, Olson
KR
et al.: Shorter duration of oral Nacetylcysteine therapy for acute
acetaminophen overdose.
Ann Emerg Med. 2000;35:363–368.
171. +
Yang
R, Miki
K, He
X
et al.: Prolonged treatment with N-acetylcysteine delays liver recovery from
acetaminophen hepatotoxicity.
Crit Care. 2009;13:R55.
172. +
Yarema
MC, Johnson
DW, Nettel-Aguirre
A
et al.: IV versus oral N-acetylcysteine. Ann Emerg Med. 2010;55:394–395.
173. +
Yarema
MC, Johnson
DW, Berlin
RJ
et al.: Comparison of the 20-hour intravenous and 72-hour oral
acetylcysteine protocols for the treatment of acute
acetaminophen poisoning. Ann Emerg Med. 2009;54:606–614.
174. +
Yi
JH, Hoover
R, McIntosh
TK, Hazell
AS: Early, transient increase in complexin I and complexin II in the cerebral cortex following traumatic brain injury is attenuated by N-acetylcysteine. J Neurotrauma. 2006;23:86–96.
175. +
Yip
L, Dart
R, Hurlbut
K: Intravenous administration of oral N-acetylcysteine. CritCare Med. 1998;26:40–43.
176. +
Yip
L, Dart
RC: A 20-hour treatment for acute
acetaminophen overdose.
N Engl J Med. 2003;348:2471–2472.
177. +
Zyoud
SH, Awang
R, Sulaiman
SAS
et al.: Incidence of adverse drug reactions induced by N-acetylcysteine in patients with
acetaminophen overdose.
Hum Exper Toxicol. 2010;29:153–160.
178. +
Zyoud
SH, Awang
R, Sulaiman
SAS, Al-Jabi
SW: Effects of delay in infusion of N-acetylcysteine on appearance of adverse drug reactions after
acetaminophen overdose: a retrospective study.
Pharmacoepidemiol Drug Saf. 2010;19:1064–1070.